Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer

Martha Estela Salcido-Neyoy, Adolfo Sierra-Santoyo, Olga Beltrán-Ramírez, José Roberto Macías-Pérez, Saúl Villa-Treviño

Abstract

AIM: To study the effect of celecoxib (CXB) on diethylnitrosamine activation through the regulation of cytochrome P450 in a hepatocarcinogenesis model.

METHODS: Six-week-old male Sprague-Dawley rats were randomly divided into five groups, a non-treated group (NT), a diethylnitrosamine-treated group (DEN), a DEN+CXB-treated group (DEN+CXB), and CXB 8 d-treated and CXB 32 day-treated groups. The effects of celecoxib on the enzymatic activities of CYP1A1, 2A, 2B1/2, and 2E1 were assessed in hepatic microsomes 24 h after DEN administration. Changes in CYP1A1 and CYP2B1/2 protein expression were also evaluated. The rate of DEN metabolism was measured by the production of the deethylation metabolite acetaldehyde, and the denitrosation metabolite nitrite.

RESULTS: DEN+CXB administration produced a significant increase in the enzymatic activities of CYP2B1/2 and 1A1, whereas it did not change the activities of CYP2A and 2E1, compared to that of the DEN group. CXB treatment for eight days did not produce a significant effect on enzymatic activity when compared to the NT group; however, when it was administered for prolonged times (CXB 32 d group), the enzymatic activities were increased in a similar pattern to those in the DEN+CXB group. The observed increase in the enzymatic activities in the DEN+CXB group was accompanied by an increase in the CYP2B1/2 protein levels; no changes were observed in the levels of CYP1A1. In vitro, CXB increased the denitrosation of DEN, a pathway of metabolic detoxification. The addition of SKF-525A, a preferential inhibitor of CYP2B, abrogated the denitrosation of DEN.

CONCLUSION: These results suggest that the mechanism of action of CXB involves enhancement of the detoxification of DEN by an increasing denitrosation via CYP2B1/2.

© 2009 The WJG Press and Baishideng. All rights reserved.

Key words: Hepatocarcinogenesis; Chemoprevention; Diethylnitrosamine; Denitrosation; Celecoxib; Cytochromes P450

Peer reviewers: Jian Wu, Associate Professor of Medicine, Internal Medicine/Transplant Research Program, University of California, Davis Medical Center, 4635 2nd Ave. Suite 1001, Sacramento CA 95817, United States; Tetsuya Mine, MD, PhD, Professor, Chief, Director of Gastroenterological Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Tokai School of Medicine, Bohsheadai, Isehara, Kanagawa 259-1193, Japan

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common tumors, with about one million new cases per...
year worldwide. Despite progress in early diagnosis and novel therapies, the overall survival of HCC patients has not been significantly improved over the last three decades. Therefore, preventive strategies are of paramount importance and need to be actively explored in order to reduce the incidence of this disease[1].

Numerous epidemiological studies have demonstrated that long-term use of cyclooxygenase-2 (COX-2) specific inhibitors, such as celecoxib (CXB), are associated with a reduced incidence of several types of cancer[2]. Studies in rodents have shown that CXB inhibits the development of chemically induced cancers, including colon, skin, urinary bladder, and breast[3-4]. The proposed mechanisms for the effects of CXB in these models include inhibition of cell proliferation, reduction of angiogenesis and induction of apoptosis[5]. Recently, we have demonstrated that CXB acts as a chemopreventive agent against the development of preneoplastic lesions induced by diethylnitrosamine (DEN), 2-acetylaminofluorene and partial hepatectomy in the modified resistant hepatocyte (MRH) model[6]. However, the exact mechanism of action by which CXB decreases liver preneoplastic lesions remains unclear, because there was no evidence of apoptosis or of changes in COX-2 expression or PGE2 production after CXB treatment. The observed reduction in proliferation markers was not sufficient to explain the reduced number of preneoplastic lesions, thus other mechanisms must be involved in the CXB effect, probably during the initial stages of hepatocarcinogenesis.

In the MRH model, DEN bioactivation is required to produce preneoplastic lesions and subsequently HCC[7]. The metabolic activation of DEN occurs during the first hours after administration, via cytochrome P450 (CYP)-dependent α-hydroxylation, which results in an ethylating agent capable of forming DNA adducts. The CYP1A1/2, 2B, 2A1/2 and 2E1 subfamilies are the major enzymes involved in the bioactivation of DEN[8-11]. In addition to the activation reaction, a denitrosation reaction may also occur, which results in nitrite production. Nitrite formation is an alternative pathway for the formation of an alkylating intermediate, and represents a carcinogen detoxification pathway[12-14]. These two pathways of DEN metabolism could occur in parallel, and although some studies suggest that both pathways are catalyzed by the same CYP enzyme, the participation of distinct isoforms must be considered. In the absence of CYP inducers, the predominant reaction is activation; nevertheless, when specific isoforms are induced, the two mechanisms compete with each other, favoring the DEN detoxification pathway[15].

Since there is no information in the literature about CYP regulation by CXB as a chemopreventive mechanism, the aim of this study was to determine the effect of CXB on DEN activation by affecting CYP regulation in the MHR model. These data demonstrate that the preferential modulation of CYP2B1/2 by CXB enhances DEN detoxification, which therefore blocks the initiation of the hepatocarcinogenic process.

MATERIALS AND METHODS

Materials
DEN was purchased from Sigma Chemical Co. (St. Louis, MO). Ethoxy- and pentoxy-resorufin were purchased from Molecular Probes, Inc. (Eugene, OR). Electrophoresis reagents were purchased from Bio-Rad (Hercules, CA). The monoclonal anti-rat CYP1A1 antibody was purchased from Oxford Biochemicals Research, Inc. (Oxford, MI). The monoclonal anti-rat CYP2B1/2 antibody was kindly provided by Dr. Colin Jefcoate (University of Wisconsin-Madison, Dept. of Pharmacology, Madison, WI). The horseradish peroxidase-conjugated goat anti-mouse IgG antibody was acquired from Pierce Protein Research Products (Rockford, IL).

Experimental diet
CXB was extracted from the commercial drug Celebrex® (Pfizer, Mexico City, Mexico). The identity and purity of the molecule was above 99%, as determined by nuclear magnetic resonance analysis in the Department of Chemistry at CINVESTAV (Mexico City, Mexico). Diet 5001 containing 1500 ppm of CXB was prepared by Purina Test Diet (Richmond, IN).

Animals
Six-week-old male Sprague-Dawley rats were purchased from Harlan Industries (Mexico City, Mexico). Rats were fed ad libitum and housed in a controlled environment with a 12 h light/dark cycle, 50% relative humidity and a temperature of 21 ± 2°C. All experiments were performed according to the guidelines established by the Institutional Animal Care Committee in agreement with Mexican Official Norm NOM-062-ZOO-1999.

Experimental procedure
After acclimation, the rats were separated into five treatment groups (Figure 1). In the non-treated (NT) group, rats were fed with 5001 basal diet and sacrificed eight days after the beginning of the experiment; the DEN and DEN+CXB groups received a single intraperitoneal dose of DEN (200 mg/kg) and were sacrificed 24 h later. The DEN group was fed the basal diet. The DEN+CXB group was pretreated with CXB from seven days before DEN administration until sacrifice. The CXB 8 d and CXB 32 d groups were treated only with CXB for the indicated times. Animals were sacrificed by cervical dislocation and the livers were then removed and processed to obtain microsomes, as described by Mayer et al[16].

Enzymatic activities
Alkoxysresorufin metabolism assays: Microsomal O-dealkylation of 7-ethoxy- (EROD, CYP1A1) and 7-pentoxy-resorufin (PROD, CYP2B1/2) were measured fluorometrically at 37°C using 530 and 585 nm excitation and emission wavelengths, respectively[16,17].

p-Nitrophenol hydroxylase (PNPH) assay: The
activity of CYP2E1 was measured by the formation of 4-nitrocatechol, which was determined spectrophotometrically at 546 nm.[19]

7α-Testosterone hydroxylation: The activity of CYP2A1 was determined in microsomal suspensions obtained from treated and control rats as previously described.[19] Protein concentration was determined by Lowry’s method[20] using bovine serum albumin as a standard.

**Immunoblot**

Microsomal proteins (15 and 30 µg/lane for CYP2B1/2 and CYP1A1, respectively) were separated by 10% SDS-PAGE. Proteins were blotted onto PVDF membranes. These membranes were blocked overnight at 4°C with 100 mmol/L glycine, 1% BSA and 5% non-fat dry milk in a PBS-1% Triton X-100 solution. Then, membranes were challenged with anti-rat CYP1A1 or 2B1/2 antibodies for 1 h at room temperature, followed by incubation with a horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The specific protein bands were visualized by chemiluminescence (Santa Cruz Biotechnology, Inc.) and exposure to radiographic film. Densitometric analysis of bands was carried out using Sigma Gel software (Jandel Scientific, San Rafael, CA).

**In vitro biotransformation of DEN by rat hepatic microsomes**

The rate of DEN metabolism in control and CXB-treated rat hepatic microsomes was measured by the production of both a deethylation metabolite, acetaldehyde, and a denitrosation metabolite, nitrite, as previously described.[21][22][23]. The enzymatic assay was performed in a final volume of 1 ml TMP buffer (50 mmol/L Tris-HCl, 10 mmol/L MgCl₂, 150 mmol/L KCl, pH 7.0) containing 0.5 mg rat hepatic microsomal protein, 1.2 mmol/L NADPH and 50 mmol/L DEN. Reactions were initiated by adding DEN and incubating at 37°C for 30 min, and were then stopped by adding 0.1 ml 25% ZnSO₄ and 0.1 ml saturated Ba(OH)₂ in an ice bath. Samples were vortexed and centrifuged at 5000 g for 10 min. One-hundred microliter aliquots of supernatant were used for nitrite measurements using a specific colorimetric assay kit (Cayman Chemical Co., Ann Arbor, MI), according to the manufacturer’s instructions. Acetaldehyde production was determined by HPLC in a Waters Liquid Chromatography model 600 using an Xterra C18 phase reverse column (3.9 × 150 mm), as previously described.[24]. As a control for CYP2B1/2-specificity, these assays were carried out in the presence of 50 mmol/L SKF-525A.

**Statistical analysis**

Data are presented as the mean ± SD. Analysis of variance (ANOVA) and the Bonferroni test were used to assess statistical differences among the tested groups, and the level of significance was set at P < 0.05. All statistical analyses were performed using SigmaStat software version 3.1 (Systat Software, Inc., Point Richmond, CA).

**RESULTS**

**CXB modulates the enzymatic activity of CYPs**

To determine whether the chemopreventive effect of CXB is associated with changes in the enzymatic activities of some CYPs, the activities of CYP1A1, CYP2A1, CYP2B1/2 and CYP2E1 were determined 24 h after DEN administration (Table 1). Eight days of CXB treatment did not produce a significant effect on any of the evaluated enzyme activities. DEN treatment significantly decreased the CYP1A1 and CYP2A1 activities by 66% and 58%, respectively, whereas CYP2B1/2 and CYP2E1 activities were increased 3.6- and 2.5-fold, respectively, in comparison to the NT group. When CXB was administered in combination with DEN (DEN+CXB group), the CYP1A1 activity was increased 3.5-fold and the CYP2B1/2 activity was increased 9-fold over the DEN group. Compared with the NT group, the increase in CYP2B1/2 activity was 33-fold, while no significant changes were observed for CYP1A1 activity. On the other hand, the DEN+CXB treatment had no influence on the activities of CYP2E1 and CYP2A1 (Table 1). Interestingly, the prolonged treatment with CXB (DEN+CXB group) produced an increase in the majority of the enzymatic activities analyzed: CYP1A1, CYP2B1/2 and CYP2E1. These results suggest that pretreatment with CXB in combination with the administration of DEN elicited a preferential induction of CYP1A1 and 2B1/2 enzymatic activities, with the 2B1/2 isoforms induced to a greater degree.

**Celecoxib induces the expression of CYP2B1/2 but not CYP1A1**

To determine whether the increases observed in the enzymatic activities of CYP1A1 and 2B1/2 were related to increases in protein levels, these isoforms were analyzed by immunoblotting. In the DEN-treated group, there were no significant differences in the protein expression of CYP1A1 and CYP2B1/2 compared to the NT group. The pretreatment with CXB in the DEN+CXB group significantly increased CYP2B1/2 protein expression (2.5-fold), but it had no significant effect on CYP1A1 protein expression compared to the DEN group (Figure 2).
Table 1  Effect of celecoxib on hepatic microsomal enzyme activities in a hepatocarcinogenesis assay

| Treatment       | CYP1A1 (μmol resorufin/min per mg protein) | CYP2B1/2 (μmol product/min per mg protein) | CYP2A1/2 (μmol 4-nitrocatechol/min per mg protein) |
|-----------------|------------------------------------------|------------------------------------------|-----------------------------------------------|
|                 | EROD (CYP1A1)                            | PROD (CYP2B1/2)                          | P-Nitrophenol hydroxylase activity           |
| NT              | 13.1 ± 0.5                               | 2.0 ± 0.5                                | 129.2 ± 18.9                                 |
| CXB 8 d         | 13.3 ± 4.3                               | 4.2 ± 2.2                                | 54.2 ± 19.2                                 |
| DEN             | 4.5 ± 1.3                                | 7.3 ± 3.2                                | 66.0 ± 5.9                                  |
| DEN+CXB         | 15.9 ± 4.8                               | 65.9 ± 35.4                              | 151.5 ± 29.5                                |
| CXB 32 d        | 54.5 ± 11.3                              | 114.2 ± 23.2                             | 1.40 ± 0.44                                 |

Male rats were treated with a single dose of DEN (200 mg/kg) ip and sacrificed 24 h after administration (DEN and DEN+CXB groups). The CXB diet was provided 7 d before DEN treatment and until sacrifice (8 d). The CXB 8 d and CXB 32 d groups received only a CXB-containing diet. Significantly different from the NT group; a From the DEN group, according to the Bonferroni test (P < 0.05). Values shown are the mean ± SD from n = 4. ND: not determined.

In summary, these results show that CXB differentially affects these two isoforms; the increase in the protein expression of CYP2B1/2 suggests that the regulation might be at the transcriptional level, while in the case of CYP1A1, CXB seems to regulate only the enzymatic activity.

CXB favors detoxification by denitrosation of DEN

To explore whether regulation of the CYP isoforms by CXB induces the detoxification pathway of DEN, we included SKF-525A in the assay, a CYP inhibitor that acts preferentially on this isoform. Inhibition of CYP2B1/2 resulted in a 98% reduction in nitrite production in the microsomes of CXB-treated rats, suggesting that CYP2B1/2 was involved in the denitrosation of DEN under basal conditions (NT animals) and CXB-induced conditions. The deethylation rate was measured by the production of acetaldehyde, which was 3.6-fold higher in the CXB group than in the NT group; a 3.6-fold increase in the rate of denitrosation of DEN, while there was no effect on DEN deethylation. This result indicates an induction of the detoxification pathway of the carcinogen. To confirm whether this effect resulted from induction of the enzymatic activity of CYP2B1/2 by CXB, we included SKF-525A in the assay, a CYP inhibitor that acts preferentially on this isoform. Inhibition of CYP2B1/2 resulted in a 98% reduction in nitrite production in the microsomes isolated from non-treated animals, and a 95% reduction in the microsomes of CXB-treated rats, suggesting that CYP2B1/2 was involved in the denitrosation of DEN under basal conditions (NT animals) and CXB-induced conditions. The deethylation rate in non-treated rat microsomes decreased 73%, and no statistically significant changes were observed in the rat microsomes treated with CXB. One possible explanation for this result is that CYP2E1 and 1A1 are minimally affected by SKF-525A and could be responsible for the acetaldehyde production under these conditions (Figure 3).

DISCUSSION

CXB has eliminated shown to have anticancer effects in...
In particular, the effect of bicyclol on CYP2B1 was of several CYP isoforms, including CYP2B1/2. Although that study demonstrated a reduction in proliferation markers and in the nuclear translocation of NF-kB, the exact mechanism of action remains unclear.

Altered expression of CYP genes is a common feature in hepatic preneoplastic and neoplastic lesions induced by various carcinogens, including DEN. Therefore, DEN metabolism via hepatic microsomal CYPs provides molecular targets for chemoprevention. This study demonstrates that the chemopreventive effect of CXB in the modified resistant hepatocyte model is mediated by changes in DEN metabolism via CYP regulation. CXB treatment for 8 d did not induce significant changes in enzymatic activities; however, when it was administered for 32 d or in combination with DEN, CXB strongly enhanced the enzymatic activity of CYP2B1/2. Moreover, CXB treatment increased the nitrite levels, which have been proposed to result from the DEN detoxification pathway. This finding supports the explanation that the chemopreventive activity of CXB is carried out by reducing carcinogen-induced DNA damage, thus preventing the initiation of hepatocarcinogenesis. We propose that the effect of CXB is due to the preferential induction of CYP2B1/2. This hypothesis is reinforced by in vitro results, where the increase in DEN denitrosation elicited by CXB was inhibited by the addition of SKF-525A, an inhibitor of several CYP isoforms including 2B1/2B2, 3A1/2 and 2A, whereas CYP2E1 and 1A are less affected.

The deethylation rate was not affected by the inhibitor, suggesting that CYP2E1, and possibly CYP1A, could be the main isoforms involved in this pathway. According to a previous report, the enzymatic activity of CYP2E1 increased with DEN treatment. This is congruent with the participation of this isoform in DEN metabolism. However, CXB did not have any effect on this increase, suggesting that there is no contribution of CYP2E1 to the chemoprotective effect of CXB. On the other hand, CXB reversed the effect of DEN on CYP1A1-specific EROD activity. A decrease in the CYP1A1 enzyme activity in preneoplastic lesions induced by DEN has been previously reported. Induction of CYP1A1 has been related to chemoprevention; thus, the induction of this isoform by CXB could explain its chemoprotective effect, but comparing the levels of enzymatic activity induced reveals that its participation is probably minor compared to CYP2B1/2. Additionally, CYP2A was not affected by CXB, and considering that it is partially affected by SKF-525A, this isoform could be involved in the deethylation reaction of DEN, although to a lesser extent than CYP2E1.

This is the first report that describes the effect of CXB on hepatic CYP regulation. Other chemoprotectors have been shown to act in a similar way. For example, among their multiple effects, diallyl sulphone, indole-3-carbinol, d-limonene and bicyclol induced the enzymatic activity of several CYP isoforms, including CYP2B1/2. In particular, the effect of bicyclol on CYP2B1 was associated with an increase in the denitrosation rate of DEN. In that case, bicyclol reduced the Km values for denitrosation below the values of deethylation, which may be attributed to the induction of specific CYPs. According to these results on DEN metabolism, the chemopreventive CXB effect in the MHR model could be similar to that of bicyclol, mediated mainly by the 2B1/2 isoform. Isoforms of the 1A, 2A, 2B and 2E CYP families share a broader overlap in substrate selectivity. In addition, a single enzyme can bind a variety of substrates, multiple substrates, and/or generate multiple products from a single substrate, which makes it difficult to discriminate between these possibilities in in vitro systems. Further studies are required to clarify the mechanism by which CXB induces the denitrosation of DEN, and whether this is generated simply by the preferential induction of isoforms or by other effects.

In summary, the modulation of several hepatic CYPs by CXB modifies the bioactivation of DEN, favoring detoxification via denitrosation. This pathway may constitute an additional mechanism of action to explain the chemoprotective effects of CXB at the initiation stage in this hepatocarcinogenesis model.

ACKNOWLEDGMENTS

We thank Dr. Angelina Flores and Sonia Sánchez for their aid in the extraction of celecoxib, Dr. Víctor Pérez and Isabel Wens for their helpful assistance with HPLC-based determinations, and Patricia Vázquez, Evelia Arce and Sergio Hernández for their technical support. We also thank Maria Antonieta López, Rafael Leyva, Manuel Flores, Ricardo Gaxiola and UPEAL Chairman Dr. Jorge Fernández at UPEAL-CINVESTAV for the animal handle and care.

COMMENTS

Background

Celecoxib, a non-steroidal antiinflammatory drug, is associated with a reduced incidence of several types of cancer, including hepatocellular carcinoma. Study of the mechanism of action has been possible by means of animal models. In the modified resistant hepatocyte model, celecoxib has shown a chemoprotector effect in the development of liver preneoplastic lesions; however, the action mechanism has not been defined completely.

Research frontiers

Diethylnitrosamine bioactivation is a crucial event in the initiation stage of the modified resistant hepatocyte model, a process dependent on hepatic cytochrome P450 (CYP). Therefore, modulation of liver CYP provides molecular targets for chemoprevention. This study demonstrates that the chemopreventive effect of celecoxib is mediated by changes in diethylnitrosamine metabolism via CYP regulation.

Innovations and breakthroughs

Recent investigations have demonstrated several mechanisms through which celecoxib exerts its chemoprotector effect. However, this is the first report that describes the capacity of celecoxib to modulate liver CYP expression and metabolism. In that case, celecoxib reduced the Km values for denitrosation below the values of deethylation, which may be attributed to the induction of specific CYPs. According to these results on DEN metabolism, the chemopreventive CXB effect in the MHR model could be similar to that of bicyclol, mediated mainly by the 2B1/2 isoform. Isoforms of the 1A, 2A, 2B and 2E CYP families share a broader overlap in substrate selectivity. In addition, a single enzyme can bind a variety of substrates, multiple substrates, and/or generate multiple products from a single substrate, which makes it difficult to discriminate between these possibilities in in vitro systems. Further studies are required to clarify the mechanism by which CXB induces the denitrosation of DEN, and whether this is generated simply by the preferential induction of isoforms or by other effects.

In summary, the modulation of several hepatic CYPs by CXB modifies the bioactivation of DEN, favoring detoxification via denitrosation. This pathway may constitute an additional mechanism of action to explain the chemoprotective effects of CXB at the initiation stage in this hepatocarcinogenesis model.

ACKNOWLEDGMENTS

We thank Dr. Angelina Flores and Sonia Sánchez for their aid in the extraction of celecoxib, Dr. Víctor Pérez and Isabel Wens for their helpful assistance with HPLC-based determinations, and Patricia Vázquez, Evelia Arce and Sergio Hernández for their technical support. We also thank Maria Antonieta López, Rafael Leyva, Manuel Flores, Ricardo Gaxiola and UPEAL Chairman Dr. Jorge Fernández at UPEAL-CINVESTAV for the animal handle and care.

COMMENTS

Background

Celecoxib, a non-steroidal antiinflammatory drug, is associated with a reduced incidence of several types of cancer, including hepatocellular carcinoma. Study of the mechanism of action has been possible by means of animal models. In the modified resistant hepatocyte model, celecoxib has shown a chemoprotector effect in the development of liver preneoplastic lesions; however, the action mechanism has not been defined completely.

Research frontiers

Diethylnitrosamine bioactivation is a crucial event in the initiation stage of the modified resistant hepatocyte model, a process dependent on hepatic cytochrome P450 (CYP). Therefore, modulation of liver CYP provides molecular targets for chemoprevention. This study demonstrates that the chemopreventive effect of celecoxib is mediated by changes in diethylnitrosamine metabolism via CYP regulation.

Innovations and breakthroughs

Recent investigations have demonstrated several mechanisms through which celecoxib exerts its chemoprotector effect. However, this is the first report that describes the capacity of celecoxib to modulate liver CYP expression and metabolism. In that case, celecoxib reduced the Km values for denitrosation below the values of deethylation, which may be attributed to the induction of specific CYPs. According to these results on DEN metabolism, the chemopreventive CXB effect in the MHR model could be similar to that of bicyclol, mediated mainly by the 2B1/2 isoform. Isoforms of the 1A, 2A, 2B and 2E CYP families share a broader overlap in substrate selectivity. In addition, a single enzyme can bind a variety of substrates, multiple substrates, and/or generate multiple products from a single substrate, which makes it difficult to discriminate between these possibilities in in vitro systems. Further studies are required to clarify the mechanism by which CXB induces the denitrosation of DEN, and whether this is generated simply by the preferential induction of isoforms or by other effects.

In summary, the modulation of several hepatic CYPs by CXB modifies the bioactivation of DEN, favoring detoxification via denitrosation. This pathway may constitute an additional mechanism of action to explain the chemoprotective effects of CXB at the initiation stage in this hepatocarcinogenesis model.

ACKNOWLEDGMENTS

We thank Dr. Angelina Flores and Sonia Sánchez for their aid in the extraction of celecoxib, Dr. Víctor Pérez and Isabel Wens for their helpful assistance with HPLC-based determinations, and Patricia Vázquez, Evelia Arce and Sergio Hernández for their technical support. We also thank Maria Antonieta López, Rafael Leyva, Manuel Flores, Ricardo Gaxiola and UPEAL Chairman Dr. Jorge Fernández at UPEAL-CINVESTAV for the animal handle and care.

COMMENTS

Background

Celecoxib, a non-steroidal antiinflammatory drug, is associated with a reduced incidence of several types of cancer, including hepatocellular carcinoma. Study of the mechanism of action has been possible by means of animal models. In the modified resistant hepatocyte model, celecoxib has shown a chemoprotector effect in the development of liver preneoplastic lesions; however, the action mechanism has not been defined completely.

Research frontiers

Diethylnitrosamine bioactivation is a crucial event in the initiation stage of the modified resistant hepatocyte model, a process dependent on hepatic cytochrome P450 (CYP). Therefore, modulation of liver CYP provides molecular targets for chemoprevention. This study demonstrates that the chemopreventive effect of celecoxib is mediated by changes in diethylnitrosamine metabolism via CYP regulation.

Innovations and breakthroughs

Recent investigations have demonstrated several mechanisms through which celecoxib exerts its chemoprotector effect. However, this is the first report that describes the capacity of celecoxib to modulate liver CYP expression and metabolism. In that case, celecoxib reduced the Km values for denitrosation below the values of deethylation, which may be attributed to the induction of specific CYPs. According to these results on DEN metabolism, the chemopreventive CXB effect in the MHR model could be similar to that of bicyclol, mediated mainly by the 2B1/2 isoform. Isoforms of the 1A, 2A, 2B and 2E CYP families share a broader overlap in substrate selectivity. In addition, a single enzyme can bind a variety of substrates, multiple substrates, and/or generate multiple products from a single substrate, which makes it difficult to discriminate between these possibilities in in vitro systems. Further studies are required to clarify the mechanism by which CXB induces the denitrosation of DEN, and whether this is generated simply by the preferential induction of isoforms or by other effects.

In summary, the modulation of several hepatic CYPs by CXB modifies the bioactivation of DEN, favoring detoxification via denitrosation. This pathway may constitute an additional mechanism of action to explain the chemoprotective effects of CXB at the initiation stage in this hepatocarcinogenesis model.
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11: 7391-7400

Terminology
CYP is hepatic microsomal protein involved in the phase I metabolism. Celecoxib is a nonsteroidal anti-inflammatory drug that specifically inhibits cyclooxygenase-2. Diethylnitrosamine is a carcinogen initiator used in the modified resistant hepatocyte model.

Peer review
The authors examined the capability of celecoxib to modulate CYP as part of its chemopreventive mechanism in the modified resistant hepatocyte model. The results suggest that celecoxib favors the diethylnitrosamine detoxification and contribute to clarifying the chemopreventive mechanism in the chemical hepatocarcinogenesis of rat.

REFERENCES

1. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11: 7391-7400
2. Rüegg C, Zoric J, Stupp R. Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hopes, hopes and reality. Ann Med 2003; 35: 476-487
3. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon cancer. Cancer Res 1998; 58: 409-412
4. Pentland AP, Schoggin JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibitor. Carcinogenesis 1999; 20: 1939-1944
5. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60: 5599-5602
6. Harris RE, Alshafie GA, Abou-issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-2103
7. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, Haugg AM, Diens HP, Breuhahn K, Schirmacher P. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885-894
8. Márquez-Rosado L, Trejo-Solís MC, García-Cuárrer CM, Villa-Treviño S. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 2005; 43: 653-660
9. Verna L, Why尼斯, Williams GM. N-nitrosodiethyamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. PharmacoL Ther 1996; 71: 57-81
10. Bellec G, Goadstuff T, Dreano Y, Menez JF, Berthou F. Effect of the length of alkyl chain on the cyclohexane P450 dependent metabolism of N-diaklylnitrosamines. Cancer Lett 1996; 100: 115-123
11. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cyclohexane P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789-1794
12. Jazwowski C, Pool BL, Preussmann R, Eisenbrand G. Fluoro-substituted N-nitrosamines. 2. Metabolism of N-nitrosodiethyamine and of fluorinated analogs in liver microsomal fractions. Carcinogenesis 1982; 3: 155-159
13. Appel KE, Rühle CS, Hildebrandt AG. Metabolic inactivation of N-nitrosamines by cyclohexane P-450 in vitro and in vivo. Jlarch Sci Publ 1984; 44:451
14. Wade D, Yang CS, Metral C, Roman JM, Hrabie JA, Riggs CW, Anjo T, Kofer PK, Mico BA. Deuterium isotope effect on denitrosation and demethylation of N-nitrosodimethylamine by rat liver microsomes. Cancer Res 1987; 47: 3373-3377
15. Mayer RT, Neiter KJ, Heubel F, Hahnemann B, Bucheister A, Mayer GK, Burke MD. 7-Alkoxynitrofurans: new fluorescent substrates for cyclohexane P450 monoxygenases. Biochem Pharmacol 1990; 40: 1645-1655
16. Burke MD, Thompson S, Eckobre CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxo- and benzoxylphenoxazines and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 1985; 34: 3337-3345
17. Lubet RA, Mayer RT, Cameron JW, Nims RW, Burke MD, Wolff T, Guengerich FP. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys 1985; 258: 43-48
18. Reinkel LA, Moyer MJ. p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inductive by ethanol. Drug Metab Dispos 1985; 13: 548-552
19. Sierra-Santoyo A, Hernández M, Albores A, Cebrián ME. DDT increases hepatic testosterone metabolism in rats. Arch Toxicol 2005; 79: 7-12
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
21. Zhu B, Liu GT, Wu RS, Strada SJ. Chemoprevention of bicyclol against hepatic preneoplastic lesions. Cancer Biol Ther 2006; 5: 1665-1673
22. Roomi MW, Ho RK, Sarma DS, Farber E. A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res 1985; 45: 564-571
23. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cyclohexane P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26: 681-693
24. Liu LL, Gong CK, Qi XM, Cai Y, Wang H, Wu XF, Xiao Y, Ren J. Altered expression of cyclohexane P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis. Acta Pharmacol Sin 2005; 26: 737-744
25. Buchmann A, Schwarz M, Schmitt R, Wolf CR, Oesch F, Kunz W. Development of cyclohexane P-450-altered preneoplastic and neoplastic lesions during nitrosamine-induced hepatocarcinogenesis in the rat. Cancer Res 1987; 47: 2911-2918
26. Guengerich FP. Influence of nutrients and other dietary materials on cyclohexane P-450 enzymes. Am J Clin Nutr 1995; 61: 652-658
27. Harrellson JP, Hennre KR, Alonso DO, Nelson SD. A comparison of substrate dynamics in human CYP2E1 and CYP2A6. Biochem Biophys Res Commun 2007; 352: 843-849
28. Atkins WM. Non-Michaelis-Menten kinetics in cyclohexane P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 2005; 45: 291-310

S- Editor Tian L, E- Editor Logan S, E- Editor Lin YP